Skip to main content
main-content
Top

02-24-2022 | Hypoglycemia | Adis Journal Club | Article

Drugs & Therapy Perspectives volume

Dasiglucagon in severe hypoglycemia: a profile of its use

share
SHARE
print
PRINT
insite
SEARCH

Authors: Yahiya Y. Syed

Abstract 

Subcutaneous dasiglucagon (Zegalogue®), a next generation glucagon analog, is a convenient and valuable addition to ready-to-use glucagon formulations for the rescue treatment of severe hypoglycemia in patients aged ≥ 6 years with diabetes. A single dose of dasiglucagon reverses insulin-induced hypoglycemia typically within 10 min in this population, without need for additional intervention. The drug is generally well tolerated, with nausea and vomiting being the most frequent adverse reactions. The overall safety profile of dasiglucagon is consistent with that expected for glucagon treatment. Dasiglucagon is available in convenient auto-injector and prefilled syringe forms that can be carried at room temperature.

View the full open access article

Adis evaluation of dasiglucagon (Zegalogue®) in severe hypoglycemia

Ready-to-use aqueous formulation; no need to reconstitute

Available in convenient auto-injector and prefilled syringe forms; can be carried at room temperature

Indicated in the USA for the rescue treatment of severe hypoglycemia in patients aged ≥ 6 years with diabetes

A single dose reverses hypoglycemia within a median 10 min, without need for additional intervention

Generally well tolerated, with nausea and vomiting being the most frequent adverse reactions

share
SHARE
print
PRINT